Stockscreener 앱 받기
81.71
0.13%
-0.11
전일 마감가:
$81.82
열려 있는:
$81.65
하루 거래량:
12.86M
Relative Volume:
0.82
시가총액:
$198.30B
수익:
$63.92B
순이익/손실:
$17.43B
주가수익비율:
11.89
EPS:
6.87
순현금흐름:
$17.04B
1주 성능:
+3.47%
1개월 성능:
+6.63%
6개월 성능:
-19.89%
1년 성능:
-36.84%
1일 변동 폭
$81.45
$82.44
1주일 범위
$78.67
$82.44
52주 변동 폭
$73.31
$134.63
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
MRK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
81.71 | 198.30B | 63.92B | 17.43B | 17.04B | 6.87 |
|
LLY
Lilly Eli Co
|
819.36 | 691.15B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
157.10 | 373.01B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
191.08 | 335.32B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVO
Novo Nordisk Adr
|
79.83 | 331.61B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
119.45 | 233.10B | 53.22B | 12.86B | 14.85B | 6.39 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Goldman Sachs Remains a Buy on Merck & Co (MRK), Sets a $99.00 PT - Insider Monkey
Merck’s SWOT analysis: stock faces keytruda LOE challenge amid pipeline promise - Investing.com
Merck (MRK) Secures Landmark FDA Approval for Keytruda in Head and Neck Cancer - Daily Chhattisgarh News
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025 - The Motley Fool
Immuno-Oncology and Precision Medicine Trends Led by Merck & Pfizer Boost Gastric Cancer Market Growth - openPR.com
SpringWorks Therapeutics’ SWOT analysis: stock outlook amid Merck acquisition - Investing.com
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit - AOL.com
Merck (MRK) Boosted by Rising MMR Vaccine Demand Amid Measles Outbreaks - GuruFocus
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda - Investopedia
FDA Approves Merck's Keytruda for Head and Neck Cancer - GuruFocus
Merck's Keytruda gains additional indications in head and neck cancer - Seeking Alpha
Merck: FDA approves Keytruda for head and neck cancer - marketscreener.com
FDA Approves Merck's Anti-PD-1 Therapy - marketscreener.com
Merck Says FDA Approves Keytruda for Head and Neck Cancer With PD-L1 Expression - marketscreener.com
FDA Approves Merck's Keytruda for Specific Head and Neck Cancer | MRK Stock News - GuruFocus
Merck (MRK) Awaits EU Approval for New Pet Medicine - GuruFocus
Merck Animal Health Gets EU Positive Opinion for Numelvi Tablets for Dogs - marketscreener.com
Merck Animal Health Receives EU Cvmp Positive Opinion For Numelvi Tablets For Dogs - marketscreener.com
Merck (MRK) Awaits EU Approval for Innovative Canine Drug | MRK Stock News - GuruFocus
RFK Jr.’s New Vaccine Panel Includes Two Paid Witnesses Against Merck - Bloomberg.com
Merck Animal Health gets EU backing for Numelvi tablets (MRK:NYSE) - Seeking Alpha
Merck’s canine dermatitis drug Numelvi gets positive EU opinion - Investing.com
Merck (MRK) Animal Health Receives EU CVMP Positive Opinion for NUMELVI Tablets for Dogs - StreetInsider
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs - Yahoo Finance
Kalkine : Is Merck Set for Strong Payouts This Dividend Season Dow Jones Industrial Average - Kalkine Media
Exclusive-Kennedy’s new vaccine adviser was expert witness against Merck vaccine - The Mighty 790 KFGO
Controversy Surrounds Merck (MRK) Due to Vaccine Litigation Ties - GuruFocus
RFK Jr’s vaccine advisor has worked against Merck shot (MRK) - Seeking Alpha
Exclusive-Kennedy's new vaccine adviser was expert witness against Merck vaccine - marketscreener.com
Merck (MRK) Initiates Late-Stage Dengue Vaccine Trial - GuruFocus
Merck: Phase 3 trial for dengue vaccine - marketscreener.com
Merck begins late-stage trial for single dose dengue vaccine - Seeking Alpha
Merck (MRK) Launches Key Phase 3 Trial for Dengue Vaccine | MRK Stock News - GuruFocus
Merck begins phase 3 trial of single-dose dengue vaccine - Investing.com Australia
Merck begins phase 3 trial of single-dose dengue vaccine By Investing.com - Investing.com Canada
Merck initiates phase 3 study for dengue vaccine in children By Investing.com - Investing.com Canada
Merck initiates phase 3 study for dengue vaccine in children - Investing.com
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate | MRK Stock News - GuruFocus
MRK Stock Quote Price and Forecast - CNN
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate - Business Wire
Here's Why Merck (MRK) Fell More Than Broader Market - Yahoo Finance
Merck’s Cholesterol Medication Achieves Primary Endpoint in Two Trials - MSN
Merck (MRK) Stock Declines 1.44%, Continuing Year-Long Downtrend - Daily Chhattisgarh News
Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA - Yahoo Finance
Unpacking the Latest Options Trading Trends in Merck & Co - Benzinga
Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty - BioWorld MedTech
ACIP Upheaval Leaves Merck & Co. In A Lurch - insights.citeline.com
10 Best Wide Moat Stocks To Buy Now - Insider Monkey
Merck Nixes Hopkins Patent on Keytruda Use in Win at Tribunal - Bloomberg Law News
Merck (MRK) Rises Higher Than Market: Key Facts - Yahoo Finance
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.09%
자본화:
|
볼륨(24시간):